Trials / Completed
CompletedNCT00306748
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug, 300 ug, 1000 ug, or Placebo to Patients With Chronic Constipation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Ironwood Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MD-1100 Acetate |
Timeline
- Start date
- 2006-03-01
- Completion
- 2006-08-01
- First posted
- 2006-03-24
- Last updated
- 2009-03-24
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00306748. Inclusion in this directory is not an endorsement.